Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
- Why There Will Be Fewer Johnson & Johnson COVID-19 Vaccines Next Week
- States Will Have 86% Fewer Johnson & Johnson Doses Next Week Than It Did This Week
- Johnson & Johnson Vaccine Batch Ruined At Baltimore Factory, Drug Giant Says
- Operation Warp Speed's Slaoui Ousted From Medical Company Board Over Misconduct Claim
- Defense Production Act Speeds Up Vaccine Production
- Moderna And Pfizer On Track To Hit Vaccine Production Goals
- Moderna And Pfizer Are On Track To Hit Vaccine Targets
- Normally Competitors, Merck To Produce Vaccines For Johnson & Johnson
- Merck Will Help Manufacture Johnson & Johnson's COVID-19 Vaccine
- FDA Aims To Be 'Nimble' On COVID-19 Vaccine Changes For Variants
- With Coronavirus Variants On The Rise, Vaccine Companies And FDA Pivot
- Moderna Increases COVID-19 Vaccine Shipments While Pfizer Lags Behind